A single dose of the typhoid conjugate vaccine, Typbar TCV, provides lasting efficacy in preventing typhoid fever in children ages nine months to 12 years old, according to a new study conducted by researchers at University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD) and led by in-country partners at the Malawi-Liverpool Wellcome Trust (MLW) Clinical Research Program.
Single dose typhoid conjugate vaccine found to provide lasting efficacy in children
